SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 906.57 |
| Enterprise Value ($M) | 809.20 |
| Book Value ($M) | 437.01 |
| Book Value / Share | 10.51 |
| Price / Book | 2.07 |
| NCAV ($M) | 193.01 |
| NCAV / Share | 4.64 |
| Price / NCAV | 4.70 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.02 |
| Return on Assets (ROA) | -0.02 |
| Return on Equity (ROE) | -0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.95 |
| Current Ratio | 3.24 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 311.30 |
| Assets | 555.30 |
| Liabilities | 118.29 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Increase Decrease Due To Revision In Calculated Weighted Average Shares | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fairmount Funds Management LLC | 7.90 | 11.15 | |
| 13G/A | Hillhouse Capital Advisors, Ltd. | 3.90 | -59.20 | |
| 13G/A | Rubric Capital Management LP | 5.96 | -16.80 | |
| 13G | BlackRock, Inc. | 9.40 | 0.00 | |
| 13D/A | Baker Bros. Advisors Lp | 7.70 | 8.54 | |
| 13G/A | Vanguard Group Inc | 8.37 | -8.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 35,777 | 208,496 | 17.16 | |
| 26,747 | 175,357 | 15.25 | |
| 24,957 | 191,739 | 13.02 | |
| 86,441 | 364,381 | 23.72 | |
| 57,628 | 277,443 | 20.77 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ITCI – Intra-Cellular Therapies, Inc. | JAZZ – Jazz Pharmaceuticals plc |
| KMDA – Kamada Ltd. | KPTI – Karyopharm Therapeutics Inc. |
| KRON – Kronos Bio, Inc. |
Financial data and stock pages provided by
Fintel.io